24-Hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost

Advances in Therapy

Volumn 31, Issue 6, 2014, Pages 592-603

  Konstas, Anastasios G P ^a   Voudouragkaki, Irini C ^a   Boboridis, Kostantinos G ^a   Haidich, Anna Bettina ^a   Paschalinou, Eleni ^a   Giannopoulos, Theodoros ^a   Dragoumis, Nikolaos D ^a   Makridis, Alexandros K ^a   Kahook, Malik Y ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

24 h intraocular pressure (IOP) control; Benzalkonium chloride; Fixed combinations; Latanoprost timolol; Ocular surface; Ophthalmology; OSD; Polyquad; Travoprost timolol

Indexed keywords

BENZALKONIUM CHLORIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; POLIDRONIUM CHLORIDE; TIMOLOL PLUS TRAVOPROST; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; NEUROPROTECTIVE AGENT; PROSTAGLANDIN F; TIMOLOL; TRAVOPROST;

ADULT; ANTERIOR EYE CHAMBER ANGLE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEAL PACHYMETRY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EXFOLIATIVE GLAUCOMA; FEMALE; GLAUCOMA; GOLDMANN APPLANATION TONOMETER; HUMAN; INTRAOCULAR PRESSURE; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MORNING DOSAGE; OPEN ANGLE GLAUCOMA; PATIENT MONITORING; PIGMENTARY GLAUCOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SITTING; SUPINE POSITION; TEAR FILM; TONOMETRY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; DRUG POTENTIATION; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PROCEDURES; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG MONITORING; DRUG SYNERGISM; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TONOMETRY, OCULAR; TRAVOPROST; TREATMENT OUTCOME;

EID: 84905401432     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0125-9     Document Type: Article

References (36)

1. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132-5. (Pubitemid 38457133)
2. Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382-9.
3. Konstas AGP, Mikropoulos D, Stewart WC. Fixed combination therapy in glaucoma. In: Shaarawy T, Hitchings R, Sherwood M, Crowston J, editors. Glaucoma. USA: Elsevier; 2009. p. 565-75.
4. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22:5-18.
5. Konstas AG, Quaranta L, Realini T. Overview of the [corrected] travoprost/timolol BAK-free fixed combination. Expert Opin Pharmacother. 2012;13:757-66.
6. Konstas AG, Mikropoulos DG, Embeslidis TA, et al. 24-h intraocular pressure control with eveningdosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye. 2010;24:1606-13.
7. Konstas AG, Haidich AB, Rossetti L, Webers C. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Eur J Ophthalmol. 2012;22:1-4.
8. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 701-13. (Pubitemid 34620348)
9. Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806-13.
10. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-34.
11. Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4: 59-64.
12. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther. 2011;28: 501-10.
13. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618-21.
14. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-5.
15. Liang H, Brignole-Baudouin F, Riancho L, et al. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium- preserved travoprost or latanoprost ophthalmic solutions. Ophth Res. 2012;48:89-101.
16. Rolando M, Crider JY, Kahook MY. Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv. 2011;8:1425-38.
17. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-5.
18. Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730-5.
19. Broadway D, Hitchings R, Grierson I. Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J Glaucoma. 1995;4:136.
20. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237-49. (Pubitemid 32553589)
21. Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocular Pharmacol Ther. 2009;25:145-52.
22. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5:75-92.
23. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for MGD. Invest Ophthalmol Vis Sci. 2011;52:1994-2005.
24. van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol. 1969;82:10-4.
25. Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510-5.
26. Quaranta L, Katsanos A, Russo A, et al. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58:26-41.
27. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four- hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898-902. (Pubitemid 41057985)
28. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four- hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94:209-13.
29. Konstas AG, Mikropoulos D, Haidich AB, et al. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009;93:481-5.
30. Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28:26-32.
31. Research in dry eye: report of the research subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5:179-93.
32. Labbe A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocular Pharmacol Ther. 2006;22:267-78. (Pubitemid 44689667)
33. Liang H, Brignole-Baudouin F, Pauly A, et al. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/ timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther. 2011;28:311-25.
34. Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012;22:34-44.
35. Kitazawa Y, Smith P, Sasaki N, et al. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye. 2011;25:1161-9.
36. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725 e1-735 e1.